Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,850JPY
6:00am GMT
Change (% chg)

¥6 (+0.23%)
Prev Close
¥2,844
Open
¥2,848
Day's High
¥2,857
Day's Low
¥2,828
Volume
2,388,800
Avg. Vol
2,507,262
52-wk High
¥2,857
52-wk Low
¥2,284

Select another date:

Wed, Dec 13 2017

BRIEF-Vernalis has entered into drug discovery collaboration with Daiichi Sankyo

* VERNALIS SAYS ‍HAS ENTERED INTO DRUG DISCOVERY COLLABORATION WITH DAIICHI SANKYO COMPANY, LIMITED UTILIZING VERNALIS' DRUG DISCOVERY PLATFORM​

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

BRIEF-R&I affirms Daiichi Sankyo's rating at "AA" and says negative outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA"-R&I

BRIEF-Daiichi Sankyo to merge with unit Asubio Pharma

* Says it will merge with wholly owned unit Asubio Pharma Co., Ltd., effective April 1, 2018

BRIEF- Daiichi Sankyo to repurchase shares for up to 50 bln yen

* Says it plans to buy back up to 28 million shares, representing 4.2 percent of outstanding, for up to 50 billion yen, during period from Nov. 1 to March 23, 2018

BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock

* Says it will buy back up to 50 billion yen ($442 million) of stock through March 23 Further company coverage: ($1 = 113.1500 yen) (Reporting By Chris Gallagher)

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage:

BRIEF-Inovalon enters into agreement with Daiichi Sankyo Inc

* Inovalon announces agreement with daiichi sankyo, inc. To support outcomes-based contracting

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca , following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.

Select another date: